- Home
- HPP vs SYRE Comparison
HPP vs SYRE Comparison
Compare HPP & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPP
- SYRE
- Stock Information
- Founded
- HPP 1997
- SYRE 2013
- Country
- HPP United States
- SYRE United States
- Employees
- HPP N/A
- SYRE N/A
- Industry
- HPP Real Estate
- SYRE Biotechnology: Pharmaceutical Preparations
- Sector
- HPP Finance
- SYRE Health Care
- Exchange
- HPP Nasdaq
- SYRE Nasdaq
- Market Cap
- HPP 940.3M
- SYRE 1.1B
- IPO Year
- HPP 2010
- SYRE 2016
- Fundamental
- Price
- HPP $2.44
- SYRE $24.46
- Analyst Decision
- HPP Hold
- SYRE Strong Buy
- Analyst Count
- HPP 11
- SYRE 5
- Target Price
- HPP $3.04
- SYRE $55.75
- AVG Volume (30 Days)
- HPP 4.2M
- SYRE 1.4M
- Earning Date
- HPP 11-05-2025
- SYRE 11-06-2025
- Dividend Yield
- HPP N/A
- SYRE N/A
- EPS Growth
- HPP N/A
- SYRE N/A
- EPS
- HPP N/A
- SYRE N/A
- Revenue
- HPP $792,977,000.00
- SYRE N/A
- Revenue This Year
- HPP N/A
- SYRE N/A
- Revenue Next Year
- HPP $6.87
- SYRE N/A
- P/E Ratio
- HPP N/A
- SYRE N/A
- Revenue Growth
- HPP N/A
- SYRE N/A
- 52 Week Low
- HPP $1.78
- SYRE $10.91
- 52 Week High
- HPP $4.67
- SYRE $40.26
- Technical
- Relative Strength Index (RSI)
- HPP 39.32
- SYRE 69.54
- Support Level
- HPP $2.31
- SYRE $23.52
- Resistance Level
- HPP $2.52
- SYRE $25.06
- Average True Range (ATR)
- HPP 0.12
- SYRE 1.31
- MACD
- HPP -0.01
- SYRE 0.13
- Stochastic Oscillator
- HPP 27.51
- SYRE 90.62
About HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.